Appropriate models for novel osteoporosis drug discovery and future perspectives

Bibliography

• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Martin TJ, Seeman E. Bone remodeling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endo Endocrinol Metab 2008;22:701-22
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61
   PubMed Web of Science ®Google Scholar
• Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2014;94:25-34
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 2005;115:3318-25
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5
   PubMed Web of Science ®Google Scholar
• Hui SL, Slemenda CW, Carey MA, et al. Choosing between predictors of fractures. J Bone Miner Res 1995;10:1816-22
   PubMed Web of Science ®Google Scholar
• Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 2014;25:1439-43
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Nuti R. Perspectives in the treatment and prevention of osteoporosis. Drugs Today (Barc) 2009;45:629-47
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87
   PubMed Web of Science ®Google Scholar
• Schwarz P, Jørgensen NR, Abrahamsen B. Status of drug development for the prevention and treatment of osteoporosis. Expert Opin Drug Discov 2014;9:245-53
   PubMed Web of Science ®Google Scholar
• Rissanen JP, Halleen JM. Models and screening assays for drug discovery in osteoporosis. Expert Opin Drug Discov 2010;5:1163-74
   PubMed Web of Science ®Google Scholar
• Copp DH, Cameron EC, Cheney BA, et al. Evidence for calcitonin--a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962;70:638-49
   PubMed Web of Science ®Google Scholar
• Gennari C. Basic aspects of calcitonin in skeletal health. In: Orwoll ES, Bilezotes M, editors. Osteoporosis: pathophysiology and clinical management, chapter 20. Humana Press, Inc; Totowa, NJ: 2003. p. 413-35
   Google Scholar
• Wallach S, Rousseau G, Martin L, et al. Effects of calcitonin on animal and in vitro models of skeletal metabolism. Bone 1999;25:509-16
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Azria M. Clinical utilization of salmon calcitonin in the treatment of osteoporosis. In: Orwoll ES, Bilezotes M, editors. Osteoporosis: pathophysiology and clinical management, chapter 21. Humana Press, Inc; Totowa, NJ: 2003. p. 437-46
   Google Scholar
• Chesnut CHIII, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
   PubMed Web of Science ®Google Scholar
• Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;ii:1151-3
   Google Scholar
• Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15:275-300
   PubMed Web of Science ®Google Scholar
• Bord S, Beavan S, Ireland D, et al. Mechanisms by which high dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. Bone 2001;29:216-22
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endo Rev 2002;23:279-302
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women’s Health Initiative. Curr Osteoporos Rep 2007;5:153-9
   PubMedGoogle Scholar
• Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American menopause society. Menopause 2008;15:584-602
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Women’s health initiative investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
   PubMed Web of Science ®Google Scholar
• Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol 2014;143:207-22
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-79
   PubMed Web of Science ®Google Scholar
• Riggs L, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas 2013;76:213-20
   PubMed Web of Science ®Google Scholar
• Santen RJ, Kagan R, Altomare CJ, et al. Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. J Clin Endocrinol Metab 2014;99:733-47
   PubMed Web of Science ®Google Scholar
• Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49:2-19
   PubMed Web of Science ®Google Scholar
• Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969;165:1264-6
   PubMed Web of Science ®Google Scholar
• Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4
   PubMed Web of Science ®Google Scholar
• Fleisch H, Russell RGG, Simpson B, et al. Prevention by a diphosphonate of immobilisation ‘osteoporosis’ in rats. Nature 1969;223:211-12
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011;49:34-41
   PubMed Web of Science ®Google Scholar
• Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272-82
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709
   PubMed Web of Science ®Google Scholar
• Reeve J, Hesp R, Williams D, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976;1:1035-8
   PubMed Web of Science ®Google Scholar
• Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980;280:1340-4
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-38
   PubMed Web of Science ®Google Scholar
• Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002;143:3230-42
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-16
   PubMed Web of Science ®Google Scholar
• Okazaki M, Potts JT, Gardella TJ. Identification and optimization of residues in PTH and PTHrP that determine altered modes of binding to the PTH/PTHrP receptor. J Bone Miner Res 2008;23:S103
   PubMed Web of Science ®Google Scholar
• Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs 2010;19:995-1005
   PubMed Web of Science ®Google Scholar
• Feurer E, Chapurlat R. Emerging drugs for osteoporosis. Expert Opin Emeriging Drugs 2014;19:1-11
   PubMed Web of Science ®Google Scholar
• Leder BZ, O’Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2015;100:697-706
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71
   PubMed Web of Science ®Google Scholar
• Ross AB, Bateman TA, Kostenuik PJ, et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 2001;12:583-8
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Kostenuik PJ, Cranmer P, et al. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporosis Int 2007;18:1073-82
   PubMed Web of Science ®Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Mineral Res 2004;19:1059-66
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31
   PubMed Web of Science ®Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-61
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483-92
   PubMed Web of Science ®Google Scholar
• Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8
   PubMed Web of Science ®Google Scholar
• Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63
   PubMed Web of Science ®Google Scholar
• Kiviranta R, Morko J, Uusitalo H, et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001;16:1444-52
   PubMed Web of Science ®Google Scholar
• Rodan SB, Duong LT. Cathepsin K-a new molecular target for osteoporosis. IBMS BoneKEy 2008;5:16-24
   Google Scholar
• Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-8
   PubMed Web of Science ®Google Scholar
• Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012;27:524-37
   PubMed Web of Science ®Google Scholar
• Williams DS, McCracken PJ, Purcell M, et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 2013;56:489-96
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-51
   PubMed Web of Science ®Google Scholar
• Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012;27:2251-8
   PubMed Web of Science ®Google Scholar
• Bonnick S, De Villiers T, Odio A, et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2013;98:4727-35
   PubMed Web of Science ®Google Scholar
• Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 2015;26:699-712
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-23
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002;70:11-19
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513-21
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Molec Genet 2001;10:537-43
   PubMed Web of Science ®Google Scholar
• Brunkow M, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot- containing protein. Am J Hum Genet 2001;68:577-89
   PubMed Web of Science ®Google Scholar
• Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39:91-7
   PubMed Web of Science ®Google Scholar
• Manolagas SC. Wnt signaling and osteoporosis. Maturitas 2014;78:233-7
   PubMed Web of Science ®Google Scholar
• Kramer I, Loots GG, Studer A, et al. Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010;25:178-89
   PubMed Web of Science ®Google Scholar
• Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 2003;22:6267-76
   PubMed Web of Science ®Google Scholar
• Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 2011;70:i119-22
   PubMed Web of Science ®Google Scholar
• Das S, Sakthiswary R. Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: a systematic review. Curr Drug Targets 2013;14:1667-74
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 2015;30:216-24
   PubMed Web of Science ®Google Scholar
• Chang MK, Kramer I, Huber T, et al. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci USA 2014;111:E5187-95
   PubMed Web of Science ®Google Scholar
• Kartner N, Manolson MF. Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target. Expert Opin Drug Discov 2014;9:505-22
   PubMed Web of Science ®Google Scholar
• Brommage R. Genetic approaches to identifying novel osteoporosis drug targets. J Cell Biochem 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• van Wijnen AJ, van de Peppel J, van Leeuwen JP, et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr Osteoporos Rep 2013;11:72-82
   PubMed Web of Science ®Google Scholar
• Krzeszinski JY, Wei W, Huynh H, et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 2014;512:431-5
   PubMed Web of Science ®Google Scholar
• Li CJ, Cheng P, Liang MK, et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest 2015;125:1509-22
   PubMed Web of Science ®Google Scholar
• Wang Y, Grainger DW. RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev 2012;64:1341-57
   PubMed Web of Science ®Google Scholar
• Wang Y, Grainger DW. Developing siRNA therapies to address osteoporosis. Ther Deliv 2013;4:1239-46
   PubMedGoogle Scholar
• Kratchmarova I, Blagoev B, Haack-Sorensen M, et al. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005;308:1472-7
   PubMed Web of Science ®Google Scholar
• Zhang H, Recker R, Lee WN, et al. Proteomics in bone research. Expert Rev Proteomics 2010;7:103-11
   PubMed Web of Science ®Google Scholar
• Evans AM, DeHaven CD, Barrett T, et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656-67
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu J, Zhu Y, et al. Therapeutic application of mesenchymal stem cells in boneand joint diseases. Clin Exp Med 2014;14:13-24
   PubMed Web of Science ®Google Scholar
• Marie PJ. Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol 2013;9:288-95
   PubMed Web of Science ®Google Scholar
• Fajardo RJ, Karim L, Calley VI, et al. A review of rodent models of type 2 diabetic skeletal fragility. J Bone Miner Res 2014;29:1025-40
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 2013;98:946-53
   PubMed Web of Science ®Google Scholar